The Role of Stress Neuromodulators in Decision Making Under Risk (Part II) (SID2)
The Role of Stress Neuromodulators in Decision Making Under Risk
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Katja Wingenfeld
- Phone Number: 49-30-450-517534
- Email: katja.wingenfeld@charite.de
Study Locations
-
-
-
Berlin, Germany
- Charite University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- right handed, high-school diploma
Exclusion Criteria:
- former & present DSM-5 axis I disorders, medication,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
placebo pill
|
placebo pill
|
|
Experimental: Clonidin
pill 0,15 mg clonidin
|
0,15mg Clonidin orally versus placebo pill
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Working Memory (n-back task)
Time Frame: 11 minutes
|
Behavioral outcome of emotional two-back task = number of correct answers / button presses
|
11 minutes
|
|
Recognition Memory (word list learning)
Time Frame: 25 minutes
|
Behavioral outcome of word recognition task = number of correctly recognized words
|
25 minutes
|
|
Blood-oxygen-level-dependent (BOLD) response
Time Frame: 46 minutes
|
fMRI data
|
46 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood pressure
Time Frame: 2.5 hours
|
Treatment check
|
2.5 hours
|
|
Heart rate
Time Frame: 2.5 hours
|
Treatment check
|
2.5 hours
|
|
salivary cortisol
Time Frame: 2.5 hours
|
Treatment check
|
2.5 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
Other Study ID Numbers
Other Study ID Numbers
- WI 3396-11
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.